Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-957-0 | CAS number: 1141852-17-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
NOAEL (subacute, rat) = 100 mg/kg bw/day (males and females)
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 15 Feb - 24 May 2011
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: RccHanTM: WIST
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 28 days and 14 days post-exposure observation period (satellite control and test groups)
- Frequency of treatment:
- once daily, 7 days/week
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 5 (main study)
5 (satellite control and high dose groups) - Control animals:
- other: yes, bidistilled water at the same dose volume as the high dose group
- Dose descriptor:
- LOAEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Dose descriptor:
- LOEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: reduced absolute and relative adrenal weights (non-adverse)
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects on food consumption, body weights, haematology, clinical chemistry, histopathology; reduced absolute and relative adrenal weights (f, non-adverse)
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- System:
- urinary
- Organ:
- bladder
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- no
- Conclusions:
- Based on the results of the subacute toxicity study, the NOAEL for Y-15866 in male and female rats was established at 100 mg/kg bw/day.
- Executive summary:
In a 28-day oral toxicity study according to OECD guideline 407 and GLP, Y-15866 was administered undiluted once daily by gavage to 5 Wistar rats per sex and group at dose levels of 100, 300 and 1000 mg/kg bw/d, respectively. A control group of 5 male and 5 female animals received bidistilled water as control. Additional 5 rats per sex in the control group and 1000 mg/kg bw/day dose group were treated for 28 days and then allowed a 14-day treatment-free recovery period. All animals survived the scheduled treatment and recovery periods. No test substance-related clinical signs were noted at the daily observations and no findings were observed at the detailed behavioural observations. In males and females, slightly reduced food consumption was noted at 300 and 1000 mg/kg bw/day, which correlated with a decrease in body weight gain and mean body weights in both sexes at the respective dose levels. In haematology parameters, significantly decreased haematocrit was noted in males and increased mean corpuscular volume in females at 1000 mg/kg bw/day. Several plasma clinical chemistry parameters were statistically significantly altered after treatment with 1000 mg/kg bw/day in males (increased triglyceride and alanine aminotransferase (ALAT), decreased calcium, protein, albumin and globulin levels) and females (decreased protein, globulin and urea levels, increased albumin/globulin ratio and chloride levels). At necropsy, no macroscopic findings related to treatment were observed. At 300 and 1000 mg/kg bw/day, reduced absolute and relative thymus weights in males and females, which were not fully reversible at the end of recovery were observed. In females of all dose groups, reduced absolute and relative adrenal weights were seen. Although no clear dose-response was noted, this finding was considered to be test item-related, as the reduction in organ weights persisted up to the end of recovery and reached statistical significance at 1000 mg/kg/day. Histopathological examination revealed treatment-related adverse effects on urinary bladder as observed by transitional cell hyperplasia and inflammatory cell infiltration in all males treated with 300 and 1000 mg/kg bw/day as well as in one female at 300 mg/kg bw/day and four females at 1000 mg/kg bw/day. After recovery, these findings were found to be irreversible in male and female animals treated with 1000 mg/kg bw/day. Based on the study results, the NOAEL for rats was established at 100 mg/kg bw/day.
Reference
All animals survived the scheduled treatment and recovery periods. No test item-related clinical signs were noted at the daily observations and no findings were observed at the detailed behavioural observations. No findings were evident at the functional observational battery performed during the fourth week of treatment. No test item-related changes in urinalysis parameters were evident. In males and females, slightly reduced food consumption was noted at 300 and 1000 mg/kg bw/day, which correlated with a decrease in body weight gain and mean body weights in both sexes at the respective dose levels. In haematology parameters, significantly decreased haematocrit was noted in males and increased mean corpuscular volume in females at 1000 mg/kg bw/day. Several plasma clinical chemistry parameters were statistically significantly altered after treatment with 1000 mg/kg bw/day in males (increased triglyceride and alanine aminotransferase (ALAT), decreased calcium, protein, albumin and globulin levels) and females (decreased protein, globulin and urea levels, increased albumin/globulin ratio and chloride levels). At necropsy, no macroscopic findings related to treatment were observed. At 300 and 1000 mg/kg bw/day, reduced absolute and relative thymus weights in males and females, which were not fully reversible at the end of recovery were observed. In females of all dose groups, reduced absolute and relative adrenal weights were seen. Although no clear dose-response was noted, this finding was considered to be test item-related, as the reduction in organ weights persisted up to the end of recovery and reached statistical significance at 1000 mg/kg/day. Histopathological examination revealed treatment-related adverse effects on urinary bladder as observed by transitional cell hyperplasia and inflammatory cell infiltration in all males treated with 300 and 1000 mg/kg bw/day as well as in one female at 300 mg/kg bw/day and four females at 1000 mg/kg bw/day.
Details from the histopathology report: “In main study, transitional cell hyperplasia was observed in 5 males (slight to moderate) and 4 females (minimal to moderate) of the high-dose group and 5 males (minimal to slight) and 1 female (minimal) of the mid-dose group. The incidence/ severity of the lesion increased dose dependently. Inflammatory cell infiltration (mostly composed of mononuclear cells) in the submucosa was observed in 5 males (slight) and 4 females (minimal to slight) of the high-dose group and 5 males (minimal to slight) and 1 female (minimal) of the mid-dose group. The incidence/ severity of the lesion increased dose-dependently. In recovery study, transitional cell hyperplasia was observed in 5 males (minimal to moderate) and 5 females (minimal) of the high-dose group. Minimal inflammatory cell infiltration in the submucosa was observed in 3 males and 4 females of the high-dose group.”
Incidence and Mean Severity Grade of Main Findings in Urinary Bladder
Finding | Group 1
| Group 2 | Group 3 | Group 4 | ||||
Main Study Animals | 5 M- | 5 F | 5 M | 5 F | 5 M | 5 F | 5 M | 5 F |
Transitional cell hyperplasia | - | - | - | - | 5/1.4 | 1/1.0 | 5/2.6 | 4/1.8 |
Inflammatory cell infiltration | - | - | - | - | 5/1.2 | 1/1.0 | 5/2.0 | 4/1.8 |
Recovery Animals | 5 M | 5 F |
| 5 M | 5 F | |||
Transitional cell hyperplasia | - | - | 5/2.2 | 5/1.0 | ||||
Inflammatory cell infiltration | - | - | 3/1.0 | 4/1.0 |
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- A reliable study is available (Klimisch 1).
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Two consecutive 7-Day range-finding gavage studies were performed in Wistar rats to determine suitable doses for treatment with the test substance Y-15866 in a subacute toxicity study (Simon, 2011). Based on the results of these preliminary tests, doses of 100, 300 and 1000 mg/kg bw/day were selected for the assessment of subacute toxicity in rats.
In a subsequent 28-day oral toxicity study according to OECD guideline 407 and GLP, Y-15866 was administered undiluted once daily by gavage to 5 Wistar rats per sex and group at dose levels of 100, 300 and 1000 mg/kg bw/day, respectively (Simon, 2011). A control group of 5 male and 5 female animals received bidistilled water as control. Additional 5 rats per sex in the control group and 1000 mg/kg bw/day dose group were treated for 28 days and then allowed a 14-day treatment-free recovery period. All animals survived the scheduled treatment and recovery periods. No test substance-related clinical signs were noted at the daily observations and no findings were observed at the detailed behavioural observations. In males and females, slightly reduced food consumption was noted at 300 and 1000 mg/kg bw/day during the treatment period, which was considered to be test item-related. During recovery, food consumption increased again in all animals. The decline in food consumption during the study correlated with a decrease in body weight gain and mean body weights in both sexes at 300 and 1000 mg/kg/day and was considered to be of adverse nature. In haematology parameters, significantly decreased haematocrit was noted in males at 1000 mg/kg bw/day. The observed increase in mean corpuscular volume in females at this dose persisted up to the end of the recovery period. Several plasma clinical chemistry parameters were statistically significantly altered after treatment with 1000 mg/kg bw/day in males (increased triglyceride and alanine aminotransferase (ALAT), decreased calcium, protein, albumin and globulin levels) and females (decreased protein, globulin and urea levels, increased albumin / globulin ratio and chloride levels). At necropsy, no macroscopic findings related to treatment were observed. At 300 and 1000 mg/kg bw/day, reduced absolute and relative thymus weights in males and females, which were not fully reversible at the end of recovery, were observed. In females of all dose groups, reduced absolute and relative adrenal weights were seen. Although no clear dose-response was noted, this finding was considered to be test item-related, as the reduction in organ weights persisted up to the end of recovery and reached statistical significance at 1000 mg/kg bw/day. Histopathological examination revealed treatment-related adverse effects on urinary bladder as observed by transitional cell hyperplasia and inflammatory cell infiltration in all males treated with 300 and 1000 mg/kg bw/day as well as in one female at 300 mg/kg bw/day and four females at 1000 mg/kg bw/day. After recovery, these findings were found to be irreversible in male and female animals treated with 1000 mg/kg bw/day. The changes in haematology and clinical biochemistry parameters as well as effects on organ weights of thymus and adrenal glands showed no correlation with macroscopic or microscopic findings and were not considered to be adverse. Based on the study results, the NOAEL for rats was established at 100 mg/kg bw/day.
It was considered that there were no urinary tract related clinical signs, there were no test item-related changes in urinalysis parameters and there were no test item-related macroscopic findings evident for the urinary tract. Histopathological effects were observed only in the urinary bladder. The changes observed in the urinary bladder during microscopic exam (transitional cell hyperplasia) are local (not systemic), generally slight or minimal to moderate and show tendency for reversibility (at the end of recovery the number of positive animals generally decreased, and the grading of severity decreased) and mononuclear infiltrates decreased. Taking this into account it is concluded that classification of Y-15886 with STOT RE 2 (urinary bladder as a target organ) is not warranted.
Justification for classification or non-classification
The available data on subacute toxicity of Y-15866 do not warrant classification STOT RE according to Regulation (EC) 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.